---
title: Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade
  glioma and synergizes with radiotherapy
date: '2024-06-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38849845/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240608181807&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: We comprehensively investigated the combination of MET
  inhibition and radiotherapy as a novel treatment option for MET-driven pHGG. Our
  seminal preclinical data package includes pharmacokinetic characterization, recapitulation
  of clinical outcomes, coinciding results from multiple complementing in vivo studies,
  and insights into molecular mechanism underlying increased efficacy. Taken together,
  we demonstrate the groundbreaking efficacy of capmatinib and radiation as a ...'
disable_comments: true
---
CONCLUSIONS: We comprehensively investigated the combination of MET inhibition and radiotherapy as a novel treatment option for MET-driven pHGG. Our seminal preclinical data package includes pharmacokinetic characterization, recapitulation of clinical outcomes, coinciding results from multiple complementing in vivo studies, and insights into molecular mechanism underlying increased efficacy. Taken together, we demonstrate the groundbreaking efficacy of capmatinib and radiation as a ...